<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089257</url>
  </required_header>
  <id_info>
    <org_study_id>06PHR03</org_study_id>
    <nct_id>NCT01089257</nct_id>
  </id_info>
  <brief_title>Cardiovascular Impairments and Obstructive Sleep Apnea Syndrome</brief_title>
  <acronym>INFRASAS</acronym>
  <official_title>Subclinical Cardiovascular Impairments in Patients With Obstructive Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Croix-Rousse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Which are the anthropometric parameters and/or of severity of the syndrome of apnea of sleep
      (SAS) which make it possible to anticipate occurred of vascular anomalies, anatomical and/or
      functional precociously found among patients SAS? Secondary objectives:

        1. Which are the anthropometric parameters and/or of severity of SAS allowing to anticipate
           occurred of early of the cardiac function and/or rhythmic anomalies found among patients
           SAS?

        2. Do there exist biological markers who allow to anticipate the early vascular lesions or
           the anomalies beginners of the cardiac function?

        3. Which are the cardiovascular effects of a treatment of SAS by Continuous Positive
           Pressure (PC) after 3 to 6 months of treatment?

        4. Do the identified early cardiovascular attacks and/or the biological anomalies make it
           possible to predict occurred of cardiovascular events in this population of patients
           carrying SAS (followed longitudinal at 5 years)?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Subclinical Cardiovascular Impairments</condition>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with obstructive sleep apnea syndrome (Apnea/Hypopnea index &gt; 15)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female from 18 to 78 years old

          -  Patients with obstructive sleep apnea syndrome (Apnea/Hypopnea index &gt; 15)

          -  ambulatory patients

          -  patients who have signed the inform consent form

          -  patients with health insurance

        Exclusion Criteria:

          -  Body Mass Index upper or equal to 30

          -  cardiovascular pathology except blood pressure hypertension

          -  known or treated diabetes

          -  pathologies with consequence on blood pressure regulation

          -  drugs intakes with consequence on blood pressure regulation

          -  patient with chronic obstructive pulmonary disease

          -  atrial fibrillation or more than 10/minute extrasystoles

          -  bedridden patients or patients with decreased mobility

          -  patients working at night or with shift work

          -  patients with carotid stenting or surgery history

          -  patients unable to sign the inform consent form

          -  patients already treated by cPAP or dental appliance for OSAS in the last 6 months

          -  pregnant or suckling female

          -  patients under supervision or trusteeship

          -  patients taking part in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis JP PEPIN, ProfessorPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Louis JP PEPIN, PhD</last_name>
    <phone>0033476765516</phone>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>France : Laboratoire d'explorations fonctionnelles du système nerveux - Functional explorations laboratory of nervous system</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia PB BEUDIN, Doctor</last_name>
      <phone>0033473751666</phone>
    </contact>
    <investigator>
      <last_name>Jean JP PONSONNAILLE, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aimé AA AMONCHOT, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick AG GREIL, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>France : Laboratoire EFCR - Functional cardiorespiratory explorations laboratory</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis JP PEPIN, ProfessorPhD</last_name>
      <phone>0033476765516</phone>
      <email>JPepin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick PL LEVY, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud RT TAMISIER, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe JB BAGUET, ProfessorPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice PF FAURE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal PD DEFAYE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>France : Laboratoire EFCR - Functional cardiorespiratory explorations laboratory</name>
      <address>
        <city>St Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric FR ROCHE, Doctor</last_name>
      <phone>0033477828300</phone>
    </contact>
    <investigator>
      <last_name>Isabelle IC COURT-FORTUNE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Séverine SF FEASSON, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol. 2003 May 7;41(9):1429-37. Review.</citation>
    <PMID>12742277</PMID>
  </reference>
  <reference>
    <citation>Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc. 2004 Aug;79(8):1036-46. Review.</citation>
    <PMID>15301332</PMID>
  </reference>
  <reference>
    <citation>Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003 Oct 8;290(14):1906-14. Review.</citation>
    <PMID>14532320</PMID>
  </reference>
  <reference>
    <citation>Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25;365(9464):1046-53.</citation>
    <PMID>15781100</PMID>
  </reference>
  <reference>
    <citation>Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005 Sep 1;172(5):613-8. Epub 2005 May 18.</citation>
    <PMID>15901608</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <name_title>Pépin Jean-Louis, Professor</name_title>
    <organization>Laboratoire du sommeil et Laboratoire d'EFCR</organization>
  </responsible_party>
  <keyword>Cardiovascular risks</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Systemic inflammation</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Peripheral Arterial Tone</keyword>
  <keyword>Positive Airway Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

